Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Combination chemotherapy of abraxane and carboplatin in elderly patients with advanced squamous cell lung cancer, phase 1/2 study (TORG1322)

Trial Profile

Combination chemotherapy of abraxane and carboplatin in elderly patients with advanced squamous cell lung cancer, phase 1/2 study (TORG1322)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Paclitaxel (Primary)
  • Indications Lung cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Sep 2019 Primary endpoint (6-month progression-free survival ) has been met according to Results presented at the 20th World Conference on Lung Cancer.
    • 10 Sep 2019 Results presented at the 20th World Conference on Lung Cancer.
    • 24 Apr 2019 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top